EUVIMEDEUVIMED entdecken
Crossref

Ripasudil, a Rho kinase inhibitor, attenuates testosterone-induced benign prostatic hyperplasia in rats: targeting inflammation, oxidative stress, and Rho kinase pathways

Randa Hisham Aljorani, Adeeb Ahmed Al-Zubaidy, Nibrass Taher Abdali

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-025-04215-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Randa Hisham Aljorani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad, Iraq. randa.mp23@ced.nahrainuniv.edu.iq. Hauptthemen laut MEDLINE: rho-Associated Kinases, Prostatic Hyperplasia, Sulfonamides, Isoquinolines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Benign prostatic hyperplasia (BPH) is the most common urological condition among elderly men. Because of modifiable metabolic risk factors, the prevalence of BPH is rising. This study aimed to investigate the therapeutic potential of ripasudil, a Rho kinase inhibitor, and also its combination with finasteride in attenuating testosterone-induced BPH in male Wistar rats. Rats were given testosterone propionate (3 mg/kg/day) for 4 weeks to develop BPH and were treated with ripasudil (3 mg/kg/day), finasteride (5 mg/k/day), or a combination of both concomitant the testosterone injection throughout the course of the study. The results revealed a significant increase in prostate index, a rise in prostate-specific antigen (PSA), and characteristic histopathological changes indicative of BPH post-testosterone administration. Additionally, testosterone induced elevation in inflammatory markers (interleukin-6 (IL-6), interleukin-1beta (IL-1β), tumor necrosis factor-alpha (TNF-α), transforming growth factor-beta (TGF-β), and nuclear factor-κB (NF-κB)), oxidative stress (increase in malondialdehyde (MDA) and decrease in glutathione (GSH)), and elevation of Rho kinase1 (ROCK1). However, intervention with ripasudil or its combination with finasteride effectively mitigated these changes possibly via anti-inflammatory, antioxidative, and ROCK inhibition properties. These findings highlight the potential of ripasudil as adjunctive therapies for BPH, offering an approach for targeting inflammation, oxidative stress, and ROCK pathways. Further research is needed to clarify the underlying mechanisms driving these therapeutic effects and validate these findings in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

rho-Associated KinasesProstatic HyperplasiaSulfonamidesIsoquinolinesUreaProtein Kinase InhibitorsAnti-Inflammatory AgentsMaleAnimalsOxidative StressRats, WistarFinasterideTestosteroneInflammationRatsProstateSignal Transduction

Stichwörter der Autor:innen

Benign prostatic hyperplasiaROCKRipasudilTestosterone

Substanzen

rho-Associated KinasesSulfonamidesFinasterideK-115IsoquinolinesUreaTestosteroneProtein Kinase InhibitorsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad, Iraq. randa.mp23@ced.nahrainuniv.edu.iq.
  • Department of Pharmacology, College of Medicine, University of Warith Al-Anbiyaa, Karbalaa, Iraq.
  • Department of Pharmacology and Toxicology, College of Pharmacy, Al-Farahidi University, Baghdad, Iraq.

Zitieren

APA

Aljorani, R. H., Al-Zubaidy, A. A., & Abdali, N. T. (2025). Ripasudil, a Rho kinase inhibitor, attenuates testosterone-induced benign prostatic hyperplasia in rats: targeting inflammation, oxidative stress, and Rho kinase pathways. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04215-7

Vancouver

Aljorani RH, Al-Zubaidy AA, Abdali NT. Ripasudil, a Rho kinase inhibitor, attenuates testosterone-induced benign prostatic hyperplasia in rats: targeting inflammation, oxidative stress, and Rho kinase pathways. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04215-7

BibTeX
@article{Aljorani2025,
  author = {Aljorani, Randa Hisham and Al-Zubaidy, Adeeb Ahmed and Abdali, Nibrass Taher},
  title = {Ripasudil, a Rho kinase inhibitor, attenuates testosterone-induced benign prostatic hyperplasia in rats: targeting inflammation, oxidative stress, and Rho kinase pathways},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-025-04215-7}
}
Kostenlos starten →